DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n3mnfs/prefeasibility) has announced the addition of the "Pre-Feasibility ...
Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Cumulative incidence (%) and 95% CI of SPM at 24 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results